Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2016, Article ID 7682472, 14 pages
http://dx.doi.org/10.1155/2016/7682472
Research Article

Development of Immunocapture-LC/MS Assay for Simultaneous ADA Isotyping and Semiquantitation

Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877, USA

Received 2 November 2015; Accepted 28 December 2015

Academic Editor: Frank-Peter Theil

Copyright © 2016 Lin-Zhi Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Schellekens, “Bioequivalence and the immunogenicity of biopharmaceuticals,” Nature Reviews Drug Discovery, vol. 1, no. 6, pp. 457–462, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. C. A. Schnabel, S. E. Fineberg, and D. D. Kim, “Immunogenicity of xenopeptide hormone therapies,” Peptides, vol. 27, no. 7, pp. 1902–1910, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Kuus-Reichel, L. S. Grauer, L. M. Karavodin, C. Knott, M. Krusemeier, and N. E. Kay, “Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies?” Clinical and Diagnostic Laboratory Immunology, vol. 1, no. 4, pp. 365–372, 1994. View at Google Scholar · View at Scopus
  4. E. Koren, L. A. Zuckerman, and A. R. Mire-Sluis, “Immune responses to therapeutic proteins in humans—clinical significance, assessment and prediction,” Current Pharmaceutical Biotechnology, vol. 3, no. 4, pp. 349–360, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Schellekens and N. Casadevall, “Immunogenicity of recombinant human proteins: causes and consequences,” Journal of Neurology, vol. 251, supplement 2, pp. II4–II9, 2004. View at Google Scholar · View at Scopus
  6. S. Tangri, B. R. Mothé, J. Eisenbraun et al., “Rationally engineered therapeutic proteins with reduced immunogenicity,” Journal of Immunology, vol. 174, no. 6, pp. 3187–3196, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. J. M. Sailstad, L. Amaravadi, A. Clements-Egan et al., “A white paper—consensus and recommendations of a global harmonization team on assessing the impact of immunogenicity on pharmacokinetic measurements,” The AAPS Journal, vol. 16, no. 3, pp. 488–498, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Shankar, S. Arkin, L. Cocea et al., “Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides—harmonized terminology and tactical recommendations,” The AAPS Journal, vol. 16, no. 4, pp. 658–673, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Shankar, C. Pendley, and K. E. Stein, “A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs,” Nature Biotechnology, vol. 25, no. 5, pp. 555–561, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. A. R. Mire-Sluis, Y. C. Barrett, V. Devanarayan et al., “Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products,” Journal of Immunological Methods, vol. 289, no. 1-2, pp. 1–16, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. J. A. Lofgren, S. Dhandapani, J. J. Pennucci et al., “Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab,” Journal of Immunology, vol. 178, no. 11, pp. 7467–7472, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Koren, H. W. Smith, E. Shores et al., “Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products,” Journal of Immunological Methods, vol. 333, no. 1-2, pp. 1–9, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. I. C. Büttel, P. Chamberlain, Y. Chowers et al., “Taking immunogenicity assessment of therapeutic proteins to the next level,” Biologicals, vol. 39, no. 2, pp. 100–109, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Shankar, V. Devanarayan, L. Amaravadi et al., “Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products,” Journal of Pharmaceutical and Biomedical Analysis, vol. 48, no. 5, pp. 1267–1281, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Gupta, S. R. Indelicato, V. Jethwa et al., “Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics,” Journal of Immunological Methods, vol. 321, no. 1-2, pp. 1–18, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Gupta, V. Devanarayan, D. Finco et al., “Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics,” Journal of Pharmaceutical and Biomedical Analysis, vol. 55, no. 5, pp. 878–888, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. A. S. Rosenberg and A. Worobec, “A risk-based approach to immunogenicity concerns of therapeutic protein products. Part 1. Considering consequences of the immune response to a protein,” BioPharm International, vol. 17, no. 11, pp. 22–26, 2004. View at Google Scholar · View at Scopus
  18. A. S. Rosenberg and A. S. Worobec, “A risk-based approach to immunogenicity concerns of therapeutic protein products, part 2: considering host-specific and product-specific factors impacting immunogenicity,” BioPharm International, vol. 17, no. 12, pp. 34–42, 2004. View at Google Scholar · View at Scopus
  19. A. S. Rosenberg and A. Worobec, “A risk-based approach to immunogenicity concerns of therapeutic protein products—part 3—effects of manufacturing changes in immunogenicity and the utility of animal immunogenicity studies,” BioPharm International, vol. 18, pp. 32–36, 2005. View at Google Scholar
  20. European Medicines Agency, “Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins,” April 2008, http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003946.pdf.
  21. U.S. Food and Drug Administration, “Guidance for industry assay development for immunogenicity testing of therapeutic proteins,” Draft Guidance, U.S. Food and Drug Administration, 2009, http://www.fda.gov/downloads/Drugs/.../Guidances/UCM192750.pdf. View at Google Scholar
  22. US Food and Drug Administration, “Guidance for industry: immunogenicity assessment for therapeutic protein products,” August 2014, http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm338856.pdf.
  23. European Medicines Agency, “Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use,” May 2012, http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128688.pdf.
  24. H. Trufelli, P. Palma, G. Famiglini, and A. Cappiello, “An overview of matrix effects in liquid chromatography-mass spectrometry,” Mass Spectrometry Reviews, vol. 30, no. 3, pp. 491–509, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. O. Heudi, S. Barteau, D. Zimmer et al., “Towards absolute quantification of therapeutic monoclonal antibody in serum by LC-MS/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry,” Analytical Chemistry, vol. 80, no. 11, pp. 4200–4207, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Pan, R. Aebersold, R. Chen et al., “Mass spectrometry based targeted protein quantification: methods and applications,” Journal of Proteome Research, vol. 8, no. 2, pp. 787–797, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. B. An, M. Zhang, and J. Qu, “Toward sensitive and accurate analysis of antibody biotherapeutics by liquid chromatography coupled with mass spectrometry,” Drug Metabolism & Disposition, vol. 42, no. 11, pp. 1858–1866, 2014. View at Publisher · View at Google Scholar
  28. M. Blackburn, “Advances in the quantitation of therapeutic insulin analogues by LC-MS/MS,” Bioanalysis, vol. 5, no. 23, pp. 2933–2946, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. V. Lange, P. Picotti, B. Domon, and R. Aebersold, “Selected reaction monitoring for quantitative proteomics: a tutorial,” Molecular Systems Biology, vol. 4, article 222, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. D. C. Liebler and L. J. Zimmerman, “Targeted quantitation of proteins by mass spectrometry,” Biochemistry, vol. 52, no. 22, pp. 3797–3806, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. M. T. Furlong, Z. Ouyang, S. Wu et al., “A universal surrogate peptide to enable LC-MS/MS bioanalysis of a diversity of human monoclonal antibody and human Fc-fusion protein drug candidates in pre-clinical animal studies,” Biomedical Chromatography, vol. 26, no. 8, pp. 1024–1032, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. W. D. Dongen, F. van Holthoon, R. Bas, and A. Kleinnijnhuis, “Low ng/mL bioanalysis of human monoclonal antibody therapeutics using UPLC-MS,” in Proceedings of the 62nd ASMS Conference on Mass Spectrometry and Allied Topics, Baltimore, Md, USA, June 2014.
  33. H. Li, R. Ortiz, L. Tran et al., “General LC-MS/MS method approach to quantify therapeutic monoclonal antibodies using a common whole antibody internal standard with application to preclinical studies,” Analytical Chemistry, vol. 84, no. 3, pp. 1267–1273, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. H. Neubert, C. Grace, K. Rumpel, and I. James, “Assessing immunogenicity in the presence of excess protein therapeutic using immunoprecipitation and quantitative mass spectrometry,” Analytical Chemistry, vol. 80, no. 18, pp. 6907–6914, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. H. W. Smith, A. Butterfield, and D. Sun, “Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA,” Regulatory Toxicology and Pharmacology, vol. 49, no. 3, pp. 230–237, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. J. S. Bourdage, C. A. Cook, D. L. Farrington, J. S. Chain, and R. J. Konrad, “An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug,” Journal of Immunological Methods, vol. 327, no. 1-2, pp. 10–17, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Patton, M. C. Mullenix, S. J. Swanson, and E. Koren, “An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen,” Journal of Immunological Methods, vol. 304, no. 1-2, pp. 189–195, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Jiang, W. Xu, C. A. Titsch et al., “Innovative use of LC-MS/MS for simultaneous quantitation of neutralizing antibody, residual drug, and human immunoglobulin G in immunogenicity assay development,” Analytical Chemistry, vol. 86, no. 5, pp. 2673–2680, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. G. S. Omenn, R. Menon, M. Adamski et al., “The human plasma and serum proteome,” in Proteomics of Human Body Fluids, vol. 3, pp. 195–224, Humana Press, 2007. View at Publisher · View at Google Scholar
  40. M. Dubois, F. Fenaille, G. Clement et al., “Immunopurification and mass spectrometric quantification of the active form of a chimeric therapeutic antibody in human serum,” Analytical Chemistry, vol. 80, no. 5, pp. 1737–1745, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. M. F. Ocaña and H. Neubert, “An immunoaffinity liquid chromatography-tandem mass spectrometry assay for the quantitation of matrix metalloproteinase 9 in mouse serum,” Analytical Biochemistry, vol. 399, no. 2, pp. 202–210, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. A. N. Hoofnagle, J. O. Becker, M. H. Wener, and J. W. Heinecke, “Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry,” Clinical Chemistry, vol. 54, no. 11, pp. 1796–1804, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. L. Borghesi and C. Milcarek, “From B cell to plasma cell: regulation of V(D)J recombination and antibody secretion,” Immunologic Research, vol. 36, no. 1–3, pp. 27–32, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. G. B. Pier, J. B. Lyczak, and L. M. Wetzler, Immunology, Infection, and Immunity, ASM Press, 2004.
  45. H. J. Gould, B. J. Sutton, A. J. Beavil et al., “The biology of IgE and the basis of allergic disease,” Annual Review of Immunology, vol. 21, pp. 579–628, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. W. E. Winter, N. S. Hardt, and S. Fuhrman, “Immunoglobulin E: importance in parasitic infections and hypersensitivity responses,” Archives of Pathology and Laboratory Medicine, vol. 124, no. 9, pp. 1382–1385, 2000. View at Google Scholar · View at Scopus
  47. M.-P. Lefranc and G. Lefranc, “Human Gm, Km, and Am allotypes and their molecular characterization: a remarkable demonstration of polymorphism,” Methods in Molecular Biology, vol. 882, pp. 635–680, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. R. Jefferis and M.-P. Lefranc, “Human immunoglobulin allotypes—possible implications for immunogenicity,” mAbs, vol. 1, no. 4, pp. 332–338, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. S. T. Wu, Z. Ouyang, T. V. Olah, and M. Jemal, “A strategy for liquid chromatography/tandem mass spectrometry based quantitation of pegylated protein drugs in plasma using plasma protein precipitation with water-miscible organic solvents and subsequent trypsin digestion to generate surrogate peptides for detection,” Rapid Communications in Mass Spectrometry, vol. 25, no. 2, pp. 281–290, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. H. Yang, J. Zhang, B. Yu, and W. Zhao, “ADA assay development and validation,” in Statistical Methods for Immunogenicity Assessment, chapter 2, pp. 23–48, CRC Press, Boca Raton, Fla, USA, 2006. View at Google Scholar
  51. Y.-M. C. Wang, L. Fang, L. Zhou, J. Wang, and H.-Y. Ahn, “A survey of applications of biological products for drug interference of immunogenicity assays,” Pharmaceutical Research, vol. 29, no. 12, pp. 3384–3392, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. N. M. Green, “Avidin and streptavidin,” in Methods in Enzymology, vol. 184, pp. 51–67, Academic Press, New York, NY, USA, 1990. View at Google Scholar
  53. D. Savage, G. Mattson, S. Desai, G. Nielander, S. Morgensen, and E. Conklin, Avidin-Biotin Chemistry: A Handbook, Pierce Chemical Company, Rockford, Ill, USA, 1992.
  54. X. Tong and L. M. Smith, “Solid-phase method for the purification of DNA sequencing reactions,” Analytical Chemistry, vol. 64, no. 22, pp. 2672–2677, 1992. View at Publisher · View at Google Scholar · View at Scopus
  55. J. Salfeld, Z. Kaymakcalan, D. Tracey, A. Roberts, and R. Kamen, “Generation of fully human anti-TNF antibody D2E7,” Arthritis & Rheumatology, vol. 41, supplement 9, article S57, 1998. View at Google Scholar